5-Star Stocks Poised to Pop: Teva

Before you go, we thought you'd like these...
Before you go close icon

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, generic-drug giant Teva Pharmaceutical Industries (NAS: TEVA) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Teva's business and see what CAPS investors are saying about the stock right now.

Teva facts

Headquarters (Founded)Petach Tikva, Israel (1901)
Market Cap$35.9 billion
IndustryPharmaceuticals
Trailing-12-Month Revenue$17.1 billion
ManagementCEO Shlomo Yanai (since 2007)
CFO Eyal Desheh (since 2008)
Return on Equity (Average, Past 3 Years)11.2%
Cash/Debt$1.1 billion / $8.2 billion
Dividend Yield1.7%
CompetitorsMylan (NAS: MYL)
Novartis (NYS: NVS)
Watson Pharmaceuticals (NYS: WPI)

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 97% of the 2,453 CAPS members who have rated Teva believe the stock will outperform the S&P 500 going forward. These bulls include ValueMan1988 and kpoeppel.

This past summer, ValueMan1988 tapped Teva as a healthy value selection:

Generic drugs are the way to go. [Teva] is cheap compared to peers. Look at the chart the last 10 years. Then look at the fundamentals. Has a dividend to top it off. [Teva] has dipped dramatically recently (so has the market) so it looks like a great time to buy. Hopefully the chart the next 10 years will look the same as it has the last 10.

In fact, Teva currently trades at a cheapish P/E of 12.1. That represents a discount to main generic rivals Mylan (19.6), Novartis (13.2), and Watson (45.3).

CAPS member kpoeppel elaborates on the bargain opportunity:

Mr. Market is depressed by the negative headlines surrounding Copaxone and [Laquinimod]. I bought [Teva] for the generics business, not for the higher-risk new drug development. I just can't bet against generics for the long term as consumers and governments try to save money on health care. ...

Generic drugs aren't going away and as global populations age, more and more will be needed. Emerging market demand will increase rapidly as basic health care will be one of the first priorities. [Teva] is an "emerging market" play that is currently out of favor from all of the negative headlines. It may be "efficiently priced" for the short term, but I believe it is mispriced for the longer term.

What do you think about Teva, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Interested in another easy way to trackTeva?Add it to your watchlist.

At the time this article was published Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Fool owns shares of Teva. Motley Fool newsletter services have recommended buying shares of Teva and Novartis. Try any of our Foolish newsletter services free for 30 days.We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.

Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners